Abstract
Erlotinib and gefitinib are quinazoline derivatives that selectively and reversibly inhibit the tyrosine kinase activity of the EGFR. Activating mutations in the EGFR confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. Erlotinib has been developed in EGFR mutation-positive patients as a first-line treatment, and results from recently completed phase III studies have shown superior progression-free survival and response rates for erlotinib, compared to chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 896-900 |
| Number of pages | 5 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 38 |
| Issue number | 6 |
| Publication status | Published - Jan 1 2011 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Erlotinib in non-small cell lung cancer. / Takeda, Masayuki; Okamoto, Isamu.
In: Japanese Journal of Cancer and Chemotherapy, Vol. 38, No. 6, 01.01.2011, p. 896-900.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Erlotinib in non-small cell lung cancer
AU - Takeda, Masayuki
AU - Okamoto, Isamu
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Erlotinib and gefitinib are quinazoline derivatives that selectively and reversibly inhibit the tyrosine kinase activity of the EGFR. Activating mutations in the EGFR confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. Erlotinib has been developed in EGFR mutation-positive patients as a first-line treatment, and results from recently completed phase III studies have shown superior progression-free survival and response rates for erlotinib, compared to chemotherapy.
AB - Erlotinib and gefitinib are quinazoline derivatives that selectively and reversibly inhibit the tyrosine kinase activity of the EGFR. Activating mutations in the EGFR confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. Erlotinib has been developed in EGFR mutation-positive patients as a first-line treatment, and results from recently completed phase III studies have shown superior progression-free survival and response rates for erlotinib, compared to chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84867001737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867001737&partnerID=8YFLogxK
M3 - Article
C2 - 21677478
AN - SCOPUS:84867001737
VL - 38
SP - 896
EP - 900
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 6
ER -